KALA BIO, Inc. (FRA:27F0)
Germany · Delayed Price · Currency is EUR 1.128
+0.397 (54.31%)
Last updated: Dec 1, 2025, 3:56 PM CET
KALA BIO Statistics
Total Valuation
KALA BIO has a market cap or net worth of EUR 9.39 million. The enterprise value is 17.00 million.
| Market Cap | 9.39M |
| Enterprise Value | 17.00M |
Important Dates
The next estimated earnings date is Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 8.21M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +86.46% |
| Shares Change (QoQ) | +8.13% |
| Owned by Insiders (%) | 0.68% |
| Owned by Institutions (%) | 20.03% |
| Float | 8.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -1.27 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.56 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.62 |
Financial Position
The company has a current ratio of 0.75
| Current Ratio | 0.75 |
| Quick Ratio | 0.65 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.93 |
| Interest Coverage | -9.20 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -65.81% |
| Return on Invested Capital (ROIC) | -79.87% |
| Return on Capital Employed (ROCE) | 551.34% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -803,876 |
| Employee Count | 38 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.42% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -87.42% |
| 50-Day Moving Average | 2.33 |
| 200-Day Moving Average | 4.84 |
| Relative Strength Index (RSI) | 37.18 |
| Average Volume (20 Days) | 50 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.11 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -35.49M |
| Pretax Income | -30.55M |
| Net Income | -30.55M |
| EBITDA | -35.21M |
| EBIT | -35.49M |
| Earnings Per Share (EPS) | -4.96 |
Balance Sheet
The company has 17.98 million in cash and 25.52 million in debt, giving a net cash position of -7.54 million.
| Cash & Cash Equivalents | 17.98M |
| Total Debt | 25.52M |
| Net Cash | -7.54M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -7.39M |
| Book Value Per Share | -0.99 |
| Working Capital | -7.07M |
Cash Flow
In the last 12 months, operating cash flow was -27.30 million and capital expenditures -71,593, giving a free cash flow of -27.37 million.
| Operating Cash Flow | -27.30M |
| Capital Expenditures | -71,593 |
| Free Cash Flow | -27.37M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KALA BIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -86.46% |
| Shareholder Yield | -86.46% |
| Earnings Yield | -325.23% |
| FCF Yield | -291.44% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 21, 2022. It was a reverse split with a ratio of 0.02.
| Last Split Date | Oct 21, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.02 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |